Accendra Health, Inc. · NYSE:ACH
Accendra Health — Q2 2026 Earnings Presentation
15 slides from Accendra Health's earnings presentation, Aug 10, 2026
Slide 1: Second Quarter 2026 Continuing Operations Supplemental Slides
Second Quarter 2026 Continuing Operations Supplemental Slides August 10, 2026
Slide 2: Safe Harbor
Safe Harbor This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This presentation contains certain “forward-looking” statements made pursuant to the S
Slide 3: Non-GAAP
Non-GAAP This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). In general, the measures exclude items and charges that (i) management does not believe reflect the Company’s core business and relate more to strat
Slide 4: About Accendra Health
About Accendra Health • Accendra Health, Inc. is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people each year. • We connect patients, providers, and insurers, delivering innovative solutions that help promote better heal
Slide 5: Accendra Health At A Glance
Accendra Health At A Glance Business Highlights ~$2.8B ~2.9 million ~2,500 • Pure-Play Patient Direct Leader Commercial Payor • Scaled Chronic Focused Portfolio FY25A Revenue Active Patients Contracts • National Footprint and Scale • Broad Payor Access and Reach Diverse Mix Across Equipment Product
Slide 6: Q2 & YTD 2026 Adjusted EBITDA and Free Cash Flow
Q2 & YTD 2026 Adjusted EBITDA and Free Cash Flow $ millions Three Months Ended Six Months Ended June 30, 2026 June 30, 2026 Loss from continuing operations, net of tax, as reported (GAAP) $ (89) $ (96) Income tax provision (benefit) 1 (8) Interest expense, net 35 67 Acquisition-related charges and i
Slide 7: Net Revenue Supplemental Information
Net Revenue Supplemental Information $ millions $682 $613 Large Commercial Payor Collection Rate Q2 2025 Actual Volume Growth Q2 2026 Actual p. 7
Slide 8: Adjusted EBITDA Supplemental Information
Adjusted EBITDA Supplemental Information(1) $ millions $97 $60 Large Commercial Payor Manufacturer Cost Q2 2026 Actual Q2 2025 Actual Net of Cost Reductions Volume / Mix Increases & Inflation Collection Rate (1) Adjusted EBITDA is a non-GAAP financial measure a reconciliation to the most comparable
Slide 9: Balance Sheet Optimization Overview
Balance Sheet Optimization Overview Balance Sheet Cash and $115M of Discount Capture Drove Significant Funded Debt Reduction $ millions 3/31/2026 6/30/2026 $450M Revolving Credit Facility 255 Term Loan A 326 Term Loan B 511 511 Unsecured Notes Due 2029 479 0 Unsecured Notes Due 2030 552 4 New $300M
Slide 10: Balance Sheet Optimization Overview
Balance Sheet Optimization Overview Pre-Balance Sheet Optimization Transaction Maturity Profile $ millions $1,000 Weighted Average Life: ~2.7 years $750 $479 $326 $500 $250 $450 $511 $552 $- 2026 2027 2028 2029 2030 2031 2032 2033 $450M Revolving Credit Facility(1) Term Loan A Term Loan B Unsecured
Slide 11: Updates to 2026 Outlooks & Modeling Assumptions
Updates to 2026 Outlooks & Modeling Assumptions Modeling Assumptions(1) Full Year 2026 Outlook Revenue $2.45 - $2.55 billion Adjusted EBITDA (2) $300 - $320 million Interest Expense (3) $142 - $146 million Diluted Weighted Average Shares Outstanding (4) ~78 million Free Cash Flow Breakeven to slight
Slide 12: Cash Flow Supplemental Information
Cash Flow Supplemental Information $ millions Three Months Ended Six Months Ended June 30, 2026 June 30, 2026 Payments for settled portion of historical P&HS-driven IRS matter - (19) Payments for legal, advisory, and other fees and expenses related to the closing of the (4) (26) divestiture of P&HS
Slide 13: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Three Months Ended June 30, (in millions) 2026 2025 Loss from continuing operations, net of tax, as reported (GAAP) $ (89) $ (84) Income tax provision (benefit) 1 (1) Interest expense, net 35 26 Acquisition-related charges and intangible amortization (1) 29 14 Transa
Slide 14: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Six Months Ended June 30, (in millions) 2026 2025 Loss from continuing operations, net of tax, as reported (GAAP) $ (96) $ (88) Income tax benefit (8) (3) Interest expense, net 67 50 Acquisition-related charges and intangible amortization (1) 58 37 Transaction breaka
Slide 15: GAAP to Non-GAAP Reconciliations, continued
GAAP to Non-GAAP Reconciliations, continued The following items have been excluded from our non-GAAP financial measures: (1) Acquisition-related charges and intangible amortization for the three and six months ended June 30, 2025 includes $6.4 million and $22 million of acquisition-related charges r